8-K: EDAP TMS Reports Record HIFU Revenue, Reiterates 2026 Guidance

EDAP TMS SA announced record fourth quarter and full-year 2025 HIFU revenue, driven by increased Focal One system sales and U.S. procedure growth, while reiterating its 2026 revenue guidance.

Summary

• EDAP TMS SA reported record High-Intensity Focused Ultrasound (HIFU) revenue for both the fourth quarter and full-year 2025.
• Full-year 2025 HIFU revenue increased by 39% year-over-year to €33.1 million ($37.4 million).
• Fourth quarter 2025 HIFU revenue grew 34% year-over-year to €11.7 million ($13.5 million).
• The company achieved a quarterly record of 15 net system placements in Q4 2025, with 14 being cash sales.
• U.S. Focal One procedures saw a 28% year-over-year growth in Q4 2025, marking the second consecutive quarter of double-digit growth.
• Total worldwide revenue for Q4 2025 decreased by 7% to €18.9 million ($21.9 million) compared to Q4 2024, primarily due to a decline in non-core businesses.
• Full-year 2025 total worldwide revenue decreased by 3% to €62.4 million ($70.5 million).
• Net loss for Q4 2025 significantly increased to €8.2 million ($9.5 million), or (€0.22) per share, from €1.9 million ($2.0 million), or (€0.05) per share, in Q4 2024.
• Full-year 2025 net loss was €25.9 million ($29.2 million), or (€0.69) per share, compared to €19.0 million ($20.6 million), or (€0.51) per share, in 2024.
• Cash and cash equivalents stood at €17.4 million ($20.5 million) as of December 31, 2025, down from €29.8 million ($31.0 million) at the end of 2024.
• The company reiterated its 2026 total revenue guidance of $72.0 million to $80.0 million, with core HIFU business revenue expected to grow between 34% and 45% year-over-year to $50.0 million to $54.0 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the core HIFU business shows impressive growth and strong future guidance, the overall company's increased net losses and significant cash burn present notable financial challenges.

Positives

• Record HIFU revenue for Q4 and full-year 2025, demonstrating strong demand for Focal One Robotic HIFU.
• Full-year 2025 HIFU revenue grew 39% year-over-year to €33.1 million ($37.4 million).
• Q4 2025 HIFU revenue increased 34% year-over-year to €11.7 million ($13.5 million).
• Achieved a quarterly record of 15 net Focal One system placements in Q4 2025, with 14 being cash sales.
• Full-year 2025 Focal One system placements grew 69% year-over-year.
• U.S. Focal One procedures increased by 28% year-over-year in Q4 2025, indicating growing adoption by urologists.
• Worldwide disposables revenue grew 43% year-over-year in Q4 2025.
• Reiterated strong 2026 HIFU business revenue guidance of $50.0 million to $54.0 million, representing 34% to 45% year-over-year growth.
• Increasing adoption of Focal One by large, integrated healthcare networks, signifying its growing importance as a technology platform.

Negatives

• Total worldwide revenue decreased by 7% in Q4 2025 to €18.9 million ($21.9 million) and by 3% for the full-year 2025 to €62.4 million ($70.5 million), primarily due to a decline in non-core businesses.
• Net loss significantly increased in Q4 2025 to €8.2 million ($9.5 million) from €1.9 million ($2.0 million) in Q4 2024.
• Full-year 2025 net loss increased to €25.9 million ($29.2 million) from €19.0 million ($20.6 million) in 2024.
• Operating loss increased in Q4 2025 to €5.2 million ($6.0 million) from €3.7 million ($4.0 million) in Q4 2024, and for the full-year 2025 to €21.9 million ($24.7 million) from €20.5 million ($22.2 million) in 2024.
• Gross margin on net sales declined to 42.6% in Q4 2025 from 44.8% in Q4 2024, impacted by tariffs and an inventory reserve.
• Cash and cash equivalents decreased significantly to €17.4 million ($20.5 million) as of December 31, 2025, from €29.8 million ($31.0 million) as of December 31, 2024, indicating substantial cash burn.

Risks

• Market acceptance and clinical status of HIFU devices may not meet expectations.
• The market potential for the lithotripsy and distribution divisions may continue to decline.
• Impact of the current worldwide inflationary environment on business operations and costs.
• Uncertain worldwide economic, political, and financial environment affecting demand and operations.
• Geopolitical instability, climate change, and pandemics or other public health crises could disrupt business operations or reduce demand for devices and services.

Future Outlook

The company reiterates its previously issued 2026 total revenue guidance of $72.0 million to $80.0 million. The core HIFU business revenue is expected to be in the range of $50.0 million to $54.0 million, representing 34% to 45% year-over-year growth in the core HIFU business.

Management Comments

• Ryan Rhodes, CEO, stated, "We experienced strong global demand for Focal One Robotic HIFU as demonstrated by our 2025 results."
• Rhodes highlighted achieving a quarterly record of 15 net system placements in Q4, with 14 being cash sales.
• Rhodes noted robust Focal One procedure growth in the U.S., reflecting increasing utilization of focal therapy for early-stage prostate cancer.
• Rhodes attributed demand for Focal One to growing clinical data, the platform's versatility, and increasing patient demand for non-invasive treatment options that preserve urinary and sexual function.
• Rhodes added that the company's pipeline continues to build, and demand for Focal One is balanced across academic and community treatment centers.
• Rhodes observed large, integrated healthcare networks purchasing multiple Focal One systems, indicating its adoption as an important technology platform.
• Rhodes expressed belief that focal therapy adoption will continue to expand globally, and the company is well-positioned to meet this growing demand.

Industry Context

StockSavvy.ai notes that EDAP TMS's strong growth in its core HIFU business aligns with broader trends favoring minimally invasive procedures and personalized medicine in oncology. The increasing adoption of Focal One in academic centers and integrated healthcare networks suggests a growing acceptance of focal therapy for prostate cancer, potentially positioning EDAP as a leader in this niche. However, the decline in non-core businesses reflects a strategic shift, which, while focusing resources, impacts overall revenue and profitability in the short term, a common challenge for companies undergoing significant portfolio restructuring.

Comparison to Industry Standards

• The 39% year-over-year growth in HIFU revenue for EDAP TMS is robust, indicating strong market penetration and adoption for its specialized technology. While direct comparable companies for focal therapy are limited, this growth rate is competitive within the high-growth medical device sector, particularly for innovative, minimally invasive oncology treatments.
• The increase in Focal One system placements by 69% year-over-year suggests a successful sales strategy and increasing capital investment by healthcare providers in advanced prostate cancer treatment technologies. This rate of adoption is strong compared to typical capital equipment sales cycles in the medical field.
• The significant increase in net loss and cash burn, despite strong core business growth, indicates that EDAP TMS is in an investment phase, common for companies scaling up new technologies. However, sustained losses and cash consumption will require careful management and potential future financing, which could be a point of concern compared to more mature, profitable medical device companies like Intuitive Surgical (ISRG) in robotic surgery or established oncology players.

Stakeholder Impact

• Shareholders: Potential for long-term value creation from strong HIFU growth, but short-term concerns due to increased losses and cash burn.
• Employees: Continued focus and investment in the HIFU business may lead to growth opportunities within that segment.
• Customers (Healthcare Providers): Increased availability and adoption of Focal One systems, offering advanced treatment options for prostate cancer.
• Patients: Greater access to non-invasive focal therapy for early-stage prostate cancer, potentially preserving urinary and sexual function.
• Creditors: The significant decrease in cash and cash equivalents may warrant closer monitoring of the company's liquidity and financial health.

Next Steps

• Attend the American Urological Association (AUA) Annual Meeting from May 15-18, 2026, in Washington, D.C.
• Host an Investor Day Meeting on June 1, 2026, at Nasdaq MarketSite, in New York City.
• Attend the Jefferies Global Healthcare Conference on June 24, 2026, in New York City.

Key Dates

Recommendation

The strong performance and positive outlook for the core HIFU business are compelling, indicating successful execution of the company's strategic focus. However, the significant increase in net losses and substantial cash burn for the overall company raise concerns about profitability and liquidity. A seasoned investor would likely 'hold' to observe if the growth in the core business can translate into improved overall financial health and reduced cash consumption in the coming quarters, especially given the reiterated 2026 guidance.

Keywords

HIFU, Focal One, Prostate Cancer, Robotic Energy-Based Therapies, Medical Devices, Urology, Minimally Invasive, Financial Results, SEC Filing, EDAP TMS